Drugs Made in America Acquisition Corp.’s (NASDAQ:DMAAU) Quiet Period Will End on March 10th

Drugs Made in America Acquisition’s (NASDAQ:DMAAU) quiet period is set to expire on Monday, March 10th. Drugs Made in America Acquisition had issued 20,000,000 shares in its initial public offering on January 28th. The total size of the offering was $200,000,000 based on an initial share price of $10.00. During Drugs Made in America Acquisition’s quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Drugs Made in America Acquisition Stock Performance

Shares of DMAAU stock opened at $10.13 on Friday. Drugs Made in America Acquisition has a 1 year low of $10.00 and a 1 year high of $10.82.

Drugs Made in America Acquisition Company Profile

Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.